


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+10.44%
-1.16%
-4.82%
+0.92%
+0.72%
BEAM
Beam Therapeutics In
$22.88
Strengths

Upgraded on attractively valued

Earnings are forecast to grow
Chart
$26.43 (-13.43%)
$16.36 (+39.85%)
$20.01 (+14.34%)
$26.68 (-14.24%)
BEAM has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

BEAM overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Earnings decline YoY

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
BEAM Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
BEAM Street Sentiment is bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayWhat is BEAM current stock price?
What are BEAM stock strengths?
What is BEAM Risk Level?
What is BEAM market cap and volume?
What is BEAM current Stock IQ?
Should I buy BEAM stock right now?
Is BEAM a Strong Buy right now?
What does a 'Strong Buy' rating mean for BEAM?
What does a 'Strong Sell' rating mean for BEAM?
What factors influence BEAM's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+10.44%
-1.16%
-4.82%
+0.92%
+0.72%
BEAM
Beam Therapeutics In
Current Price
$22.88
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Chart
$26.43 (-13.43%)
$16.36 (+39.85%)
$20.01 (+14.34%)
$26.68 (-14.24%)
BEAM Analysts Opinion
BEAM Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Earnings decline YoY

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
BEAM Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
BEAM Street Sentiment is bullish and have positive views on the near-term outlook
BEAM has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

Average key support and resistance price levels.
BEAM Latest Analysis
Beam Therapeutics (BEAM) Strengthens Cash Position as Key Trials Move Forward. Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best gene-editing stocks to buy according to hedge funds. On November 14 Beam Therapeutics Inc. (NASDAQ:BEAM) announced Q3 2025 results in which it reported wider losses than last years. The reported net loss was $112.7 million ($1.10/share) higher than $96.7 million ($1.17/share) for Q3 2024. Management attributed [….]
Tue Nov 18, 2025
Clear Street Raises PT on Beam Therapeutics (BEAM) to $37 Following Q3 Results. With significant upside potential and hedge fund interest Beam Therapeutics Inc. (NASDAQ:BEAM) secured a spot on our list of the 15 stocks set to explode in 2026. On November 5 2025 Clear Street increased its price target on Beam Therapeutics Inc. (NASDAQ:BEAM) from $34 to $37 while maintaining a Buy rating. The revised target reflected [….]
Tue Nov 11, 2025
BEAM Crosses Below Key Moving Average Level. In trading on Friday shares of Beam Therapeutics Inc (Symbol: BEAM) crossed below their 200 day moving average of $21.50 changing hands as low as $21.36 per share. Beam Therapeutics Inc shares are currently trading down about 7.2% on the day. The chart below shows the one ye
Fri Nov 7, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
BEAM Stock trends
BEAM Stock performance
BEAM Stock analysis
BEAM investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.